IL17A and bronchopulmonary dysplasia: The above experimental evidence confirmed that HBM‐Exo might inhibit the expression of the downstream target gene FADD by inhibiting the IL‐17 signalling pathway, thereby reducing cell apoptosis, finally repairing the damage of alveolar epithelial cells, thus playing a role in the prevention and treatment of BPD.